Brokerages predict that Kadmon Holdings Inc (NYSE:KDMN) will report $340,000.00 in sales for the current quarter, according to Zacks. Two analysts have made estimates for Kadmon’s earnings, with the highest sales estimate coming in at $480,000.00 and the lowest estimate coming in at $200,000.00. Kadmon posted sales of $430,000.00 during the same quarter last year, which suggests a negative year over year growth rate of 20.9%. The firm is expected to issue its next quarterly earnings report on Tuesday, May 14th.

According to Zacks, analysts expect that Kadmon will report full year sales of $3.87 million for the current fiscal year, with estimates ranging from $1.54 million to $6.20 million. For the next year, analysts anticipate that the company will report sales of $27.68 million, with estimates ranging from $16.80 million to $38.56 million. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for Kadmon.

Kadmon (NYSE:KDMN) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.18). Kadmon had a negative net margin of 3,848.01% and a negative return on equity of 192.20%.

A number of research firms have issued reports on KDMN. Zacks Investment Research raised shares of Kadmon from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a report on Friday, February 22nd. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of Kadmon in a report on Tuesday, March 12th. Finally, Citigroup raised shares of Kadmon from a “neutral” rating to a “buy” rating and set a $2.77 price objective for the company in a report on Tuesday, February 26th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $8.36.

KDMN stock traded up $0.05 during midday trading on Friday, hitting $2.16. The company’s stock had a trading volume of 13,516 shares, compared to its average volume of 869,470. The company has a current ratio of 4.12, a quick ratio of 4.08 and a debt-to-equity ratio of 0.60. Kadmon has a twelve month low of $1.88 and a twelve month high of $4.39.

Several large investors have recently modified their holdings of the company. OppenheimerFunds Inc. raised its position in shares of Kadmon by 17.5% in the 1st quarter. OppenheimerFunds Inc. now owns 35,264 shares of the company’s stock valued at $93,000 after buying an additional 5,263 shares in the last quarter. IFP Advisors Inc raised its position in shares of Kadmon by 54.5% in the 4th quarter. IFP Advisors Inc now owns 25,500 shares of the company’s stock valued at $49,000 after buying an additional 9,000 shares in the last quarter. Amalgamated Bank acquired a new position in shares of Kadmon in the 4th quarter valued at approximately $25,000. Capital Investment Advisors LLC acquired a new position in shares of Kadmon in the 4th quarter valued at approximately $26,000. Finally, Sawtooth Solutions LLC raised its position in shares of Kadmon by 3.7% in the 1st quarter. Sawtooth Solutions LLC now owns 342,217 shares of the company’s stock valued at $903,000 after buying an additional 12,357 shares in the last quarter. Institutional investors own 65.50% of the company’s stock.

Kadmon Company Profile

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.

Featured Article: Commodities

Get a free copy of the Zacks research report on Kadmon (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.